Neurosense Therapeutics Ltd. (NRSN)
US Market

Neurosense Therapeutics Ltd. (NRSN) Financial Statements


Neurosense Therapeutics Ltd. Financial Overview

Neurosense Therapeutics Ltd.'s market cap is currently ―. The company's EPS TTM is $-0.923; its P/E ratio is -0.86; Neurosense Therapeutics Ltd. is scheduled to report earnings on March 20, 2024, and the estimated EPS forecast is $-0.20. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue-$ 0.00$ 0.00$ 0.00-
Gross Profit-----
EBIT-$ -2.98M$ -3.45M$ -2.69M-
EBITDA-$ -2.98M$ -3.45M$ -2.69M-
Net Income Common Stockholders-$ -2.99M$ -3.48M$ -2.71M-
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 3.58M$ 8.44M$ 10.37M$ 13.74M$ 11.06M
Total Assets$ 7.71M$ 9.23M$ 11.45M$ 14.36M$ 11.43M
Total Debt$ 147.00K$ 173.00K$ 190.00K$ 207.00K$ 0.00
Net Debt$ -3.44M$ -8.27M$ -10.18M$ -13.53M$ -11.06M
Total Liabilities$ 2.09M$ 1.38M$ 1.62M$ 2.25M$ 2.42M
Stockholders Equity$ 5.62M$ 7.85M$ 9.84M$ 12.11M$ 9.01M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in USD

Neurosense Therapeutics Ltd. Earnings and Revenue History

Neurosense Therapeutics Ltd. Debt to Assets

Neurosense Therapeutics Ltd. Cash Flow

Neurosense Therapeutics Ltd. Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis